Journal of Neuro-Oncology

, Volume 78, Issue 1, pp 31–39 | Cite as

The efficacy of alginate encapsulated CHO-K1 single chain-TRAIL producer cells in the treatment of brain tumors

  • Jos MA Kuijlen
  • Bart J de Haan
  • Wijnand Helfrich
  • Jan-Freark de Boer
  • Douwe Samplonius
  • Jan Jakob A Mooij
  • Paul de Vos



Patients with astrocytic tumors in the central nervous system (CNS) have low survival rates despite surgery and radiotherapy. Innovative therapies and strategies must be developed to prolong survival of these patients. The alginate microencapsulation method, used to continuously release a certain cytotoxic agent in the vicinity of the tumor, is such a novel therapeutic strategy. The biological functionality of the apoptosis inducing scFv425:sTRAIL protein, which was released through the microencapsulation method, was studied in vitro. Analysis of the intracerebral biocompatibility of alginate capsules was performed by implantation of empty alginate capsules in the brain of mice.


Chinese Hamster Ovary cells (CHO-K1) were recombinantly engineered to produce the single chain anti-EGFR-sTRAIL protein (scFv425:sTRAIL). The CHO-K1 producer cells were encapsulated in an alginate capsule with a semi-permeable membrane through which the scFv425:sTRAIL protein could be released.


In vitro studies show maintained biological functionality of the released scFv425:sTRAIL protein. There was no immunological tissue response detectable after intracerebral implantation of the alginate capsules in mice brains.


Biological functionality of the produced scFv425:sTRAIL protein is maintained and intracerebral biocompatibility of the capsules is warranted. Alginate encapsulation of CHO-K1 - scFv425:sTRAIL - producer cells and subsequently their intracerebral implantation is technically feasible. This study justifies further in vivo experiments.


alginate brain EGFR encapsulation TRAIL tumor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



We acknowledged F Zuiderveen, R Horn and L van Genne for their technical assistance.


  1. 1.
    Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH, Safety and antitumor activity of recombinant soluble Apo2 ligandJ Clin Invest 104: 155–162, 1999PubMedCrossRefGoogle Scholar
  2. 2.
    Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A, Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapyProc Natl Acad Sci USA 97: 1754–1759, 2000CrossRefPubMedGoogle Scholar
  3. 3.
    Arizono Y, Yoshikawa H, Naganuma H, Hamada Y, Nakajima Y, Tasaka K, A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agentsBr J Cancer 88: 298–306, 2003CrossRefPubMedGoogle Scholar
  4. 4.
    Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P, Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types FEBS Lett 482: 193–199, 2000CrossRefPubMedGoogle Scholar
  5. 5.
    Roth W, Isenmann S, Naumann U, Kugler S, Bahr M, Dichgans J, Ashkenazi A, Weller M, Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicityBiochem Biophys Res Commun 265: 479–483, 1999CrossRefPubMedGoogle Scholar
  6. 6.
    Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH, Tumoricidal activity of tumor necrosis factor-related apoptosis- inducing ligand in vivoNat Med 5: 157–163, 1999CrossRefPubMedGoogle Scholar
  7. 7.
    French LE, Tschopp J, The TRAIL to selective tumor deathNat Med 5: 146–147, 1999CrossRefPubMedGoogle Scholar
  8. 8.
    Kim K, Fisher MJ, Xu SQ, El Deiry WS, Molecular determinants of response to TRAIL in killing of normal and cancer cellsClin Cancer Res 6: 335–346, 2000PubMedGoogle Scholar
  9. 9.
    Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U, Peters N, Scheurich P, Pfizenmaier K, Differential activation of TRAIL-R1 and −2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivativeOncogene 20: 4101–4106, 2001CrossRefPubMedGoogle Scholar
  10. 10.
    Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ: Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells Oncogene 13: 5789–5798, 2001Google Scholar
  11. 11.
    Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, Helfrich W, Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2Int J Cancer 109: 281–290, 2004CrossRefPubMedGoogle Scholar
  12. 12.
    Emerich DF, Winn SR, Hantraye PM, Peschanski M, Chen EY, Chu Y, McDermott P, Baetge EE, Kordower JH, Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington’s diseaseNature 386: 395–399, 1997CrossRefPubMedGoogle Scholar
  13. 13.
    Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM, Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNFScience 265: 1107–1110, 1994PubMedCrossRefGoogle Scholar
  14. 14.
    Winn SR, Wahlberg L, Tresco PA, Aebischer P, An encapsulated dopamine-releasing polymer alleviates experimental parkinsonism in ratsExp Neurol 105: 244–250, 1989CrossRefPubMedGoogle Scholar
  15. 15.
    Read TA, Farhadi M, Bjerkvig R, Olsen BR, Rokstad AM, Huszthy PC, Vajkoczy P, Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cellsCancer Res 61: 6830–6837, 2001PubMedGoogle Scholar
  16. 16.
    Thorsen F, Read TA, Lund-Johansen M, Tysnes BB, Bjerkvig R, Alginate-encapsulated producer cells: a potential new approach for the treatment of malignant brain tumorsCell Transplant 9: 773–783, 2000PubMedGoogle Scholar
  17. 17.
    Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF, Abe T, Carroll RS, Black PM, Continuous release of endostatin from microencapsulated engineered cells for tumor therapyNat Biotechnol19: 35–39, 2001CrossRefPubMedGoogle Scholar
  18. 18.
    de Vos P, Hamel AF, Tatarkiewicz K, Considerations for successful transplantation of encapsulated pancreatic isletsDiabetologia 45: 159–173, 2002CrossRefPubMedGoogle Scholar
  19. 19.
    Uludag H, de Vos P, Tresco PA, Technology of mammalian cell encapsulation Adv Drug Deliv Rev 42: 29–64, 2000CrossRefPubMedGoogle Scholar
  20. 20.
    de Vos P, van Hoogmoed CG, de Haan BJ, Busscher HJ, Tissue responses against immunoisolating alginate-PLL capsules in the immediate posttransplant periodJ Biomed Mater Res 62: 430–437, 2002CrossRefPubMedGoogle Scholar
  21. 21.
    Wolters GH, Fritschy WM, Gerrits D, van Schilfgaarde R, A versatile alginate droplet generator applicable for microencapsulation of pancreatic isletsJ Appl Biomater 3: 281–286, 1991CrossRefPubMedGoogle Scholar
  22. 22.
    Fritschy WM, Gerrits PO, Wolters GH, Pasma A, van Schilfgaarde R, Glycol methacrylate embedding of alginate-polylysine microencapsulated pancreatic isletsBiotech Histochem 70: 188–193, 1995PubMedGoogle Scholar
  23. 23.
    Rokstad AM, Holtan S, Strand B, Steinkjer B, Ryan L, Kulseng B, Skjak-Braek G, Espevik T, Microencapsulation of cells producing therapeutic proteins: optimizing cell growth and secretionCell Transplant 11: 313–324, 2002PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • Jos MA Kuijlen
    • 1
    • 3
  • Bart J de Haan
    • 2
  • Wijnand Helfrich
    • 2
  • Jan-Freark de Boer
    • 2
  • Douwe Samplonius
    • 2
  • Jan Jakob A Mooij
    • 1
  • Paul de Vos
    • 2
  1. 1.Department of Neurosurgery University Medical Centre Groningen, University of GroningenRB, GroningenThe Netherlands
  2. 2.Department of Pathology and Laboratory MedicineUniversity Medical Centre Groningen, University of GroningenRB, GroningenThe Netherlands
  3. 3.Department of Neurosurgery University Medical Centre GroningenRB GroningenThe Netherlands

Personalised recommendations